title: Evidence that the acute phase of ischemic preconditioning does not require signaling by the A 2B adenosine receptor.
abstract: Ischemic preconditioning (IPC) is a protective phenomenon in which brief ischemia renders the myocardium resistant to subsequent ischemic insults. Here, we used A(2B)AR gene knock-out (A(2B)KO)/β-galactosidase reporter gene knock-in mice and the A(2B)AR antagonist ATL-801 to investigate the potential involvement of the A(2B)AR in IPC, focusing on the acute phase of protection. Cardioprotection provided by acute IPC elicited by two 3-min occlusion/3-min reperfusion cycles was readily apparent in an isolated, Langendorff-perfused mouse heart model in studies using hearts from A(2B)KO mice. IPC equivalently improved the recovery of contractile function following 20 min of global ischemia and 45 min of reperfusion in both WT and A(2B)KO hearts by ~30-40%, and equivalently decreased the release of cardiac troponin I during the reperfusion period (from 5969 ± 925 to 1595 ± 674 ng/g and 4376 ± 739 to 2278 ± 462 ng/g using WT and A(2B)KO hearts, respectively). Similarly, the infarct size-reducing capacity of acute IPC in an in vivo model of infarction was fully manifested in experiments using A(2B)KO mice, as well as in experiments using rats pretreated with ATL-801. We did observe, however, a marked reduction in infarct size in rats following administration of the selective A(2B)AR agonist BAY 60-6583 (~25% reduction at a dose of 1.0mg/kg). While supportive of its concept as a cardioprotective receptor, these experiments indicate that the mechanism of the early phase of IPC is not dependent on signaling by the A(2B)AR. We present the idea that the A(2B)AR may contribute to the later stages of IPC dependent on the induction of stress-responsive genes.
authors.affiliation: Department of Pharmacology, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226, USA.
authors.forename: Jason E
authors.initials: JE
authors.lastname: Maas
authors.forename: Tina C
authors.initials: TC
authors.lastname: Wan
authors.forename: Robert A
authors.initials: RA
authors.lastname: Figler
authors.forename: Garrett J
authors.initials: GJ
authors.lastname: Gross
authors.forename: John A
authors.initials: JA
authors.lastname: Auchampach
mesh_terms: D000631:Aminopyridines / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D006334:Heart Function Tests; D006339:Heart Rate / Q000187:drug effects; D066298:In Vitro Techniques; D019157:Ischemic Preconditioning, Myocardial; D051379:Mice; D008810:Mice, Inbred C57BL; D009203:Myocardial Infarction / Q000150:complications / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D015428:Myocardial Reperfusion Injury / Q000150:complications / Q000378:metabolism / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D043704:Receptor, Adenosine A2B / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000631:Aminopyridines; C518875:BAY 60-6583; D043704:Receptor, Adenosine A2B
references.citation: Circulation. 1986 Nov;74(5):1124-36
references.pmid: 3769170
references.citation: Am J Physiol Heart Circ Physiol. 2006 Apr;290(4):H1469-73
references.pmid: 16299262
references.citation: J Mol Cell Cardiol. 1996 Mar;28(3):447-54
references.pmid: 9011628
references.citation: Circ Res. 2000 Nov 24;87(11):972-83
references.pmid: 11090541
references.citation: Br J Pharmacol. 2008 Sep;155(1):127-37
references.pmid: 18536750
references.citation: Am J Cardiol. 1997 Jun 19;79(12A):2-10
references.pmid: 9223356
references.citation: Circulation. 1991 Jul;84(1):350-6
references.pmid: 2060105
references.citation: Am J Physiol. 1990 Dec;259(6 Pt 2):H1822-5
references.pmid: 2260706
references.citation: Circulation. 1998 Sep 8;98(10):1022-9
references.pmid: 9737523
references.citation: Circulation. 1991 Dec;84(6):2504-12
references.pmid: 1959200
references.citation: Cardiovasc Res. 1992 May;26(5):456-61
references.pmid: 1446315
references.citation: FASEB J. 1995 Mar;9(5):359-65
references.pmid: 7896004
references.citation: Cardiovasc Drugs Ther. 2010 Jun;24(3):225-34
references.pmid: 20505987
references.citation: Circ Res. 1990 Apr;66(4):913-31
references.pmid: 2317895
references.citation: Circulation. 2008 Jul 8;118(2):166-75
references.pmid: 18591435
references.citation: Cardiovasc Res. 2006 May 1;70(2):308-14
references.pmid: 16545350
references.citation: Am J Physiol. 1993 May;264(5 Pt 2):H1327-36
references.pmid: 8498546
references.citation: J Pharmacol Exp Ther. 2008 Jan;324(1):234-43
references.pmid: 17906066
references.citation: Am J Physiol. 1991 Mar;260(3 Pt 2):H796-804
references.pmid: 2000974
references.citation: Am J Physiol Heart Circ Physiol. 2009 Jul;297(1):H47-52
references.pmid: 19448143
references.citation: Basic Res Cardiol. 2008 May;103(3):203-15
references.pmid: 17999026
references.citation: Cardiovasc Res. 1998 Oct;40(1):74-87
references.pmid: 9876319
references.citation: Circulation. 2007 Mar 27;115(12):1581-90
references.pmid: 17353435
references.citation: J Pharmacol Exp Ther. 2006 Dec;319(3):1200-10
references.pmid: 16985166
references.citation: J Clin Invest. 2006 Jul;116(7):1913-23
references.pmid: 16823489
references.citation: J Mol Cell Cardiol. 2007 Sep;43(3):262-71
references.pmid: 17632123
references.citation: J Mol Cell Cardiol. 2009 Nov;47(5):684-90
references.pmid: 19695259
references.citation: J Mol Cell Cardiol. 1997 Aug;29(8):2285-98
references.pmid: 9281459